These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 26011594)

  • 1. Editorial Comment from Dr Stamatiou to Clinical outcomes of prostate cancer patients in Yokosuka City, Japan: A comparative study between cases detected by prostate-specific antigen-based screening in Yokosuka and those detected by other means.
    Stamatiou KN
    Int J Urol; 2015 Aug; 22(8):753. PubMed ID: 26011594
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial Comment from Dr Izumi to Clinical outcomes of prostate cancer patients in Yokosuka City, Japan: A comparative study between cases detected by prostate-specific antigen-based screening in Yokosuka and those detected by other means.
    Izumi K
    Int J Urol; 2015 Aug; 22(8):752-3. PubMed ID: 26011512
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical outcomes of prostate cancer patients in Yokosuka City, Japan: A comparative study between cases detected by prostate-specific antigen-based screening in Yokosuka and those detected by other means.
    Sakai N; Taguri M; Kobayashi K; Noguchi S; Ikeda S; Koh H; Satomi Y; Furuhata A
    Int J Urol; 2015 Aug; 22(8):747-52. PubMed ID: 26011393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Five-year results of prostate specific antigen (PSA) screening in Yokosuka City--comparative study between PSA-screened group and non-screened group].
    Noguchi S; Satomi Y; Sakai N; Takemura H; Ikeda S; Okui N; Kobayashi M; Fukuoka H; Furuhata A
    Hinyokika Kiyo; 2008 Mar; 54(3):197-201. PubMed ID: 18411775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recommendations on screening for prostate cancer with the prostate-specific antigen test.
    Bell N; Connor Gorber S; Shane A; Joffres M; Singh H; Dickinson J; Shaw E; Dunfield L; Tonelli M;
    CMAJ; 2014 Nov; 186(16):1225-34. PubMed ID: 25349003
    [No Abstract]   [Full Text] [Related]  

  • 6. Editorial Comment to Prostate-specific antigen-based prostate cancer screening: Past and future.
    Sakamoto S
    Int J Urol; 2015 Jun; 22(6):532-3. PubMed ID: 25854711
    [No Abstract]   [Full Text] [Related]  

  • 7. Prostate-specific antigen-based population screening for prostate cancer: current status in Japan and future perspective in Asia.
    Kitagawa Y; Namiki M
    Asian J Androl; 2015; 17(3):475-80. PubMed ID: 25578935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Words of wisdom: Re: Comparative effectiveness of alternative prostate-specific antigen-based prostate cancer screening strategies: model estimates of potential benefits and harms.
    Vickers A
    Eur Urol; 2013 Oct; 64(4):682-3. PubMed ID: 23998500
    [No Abstract]   [Full Text] [Related]  

  • 9. Prostate-specific antigen, prostate cancer screening, and the pathologist: what should be our role?
    Jackson BR
    Arch Pathol Lab Med; 2013 Mar; 137(3):308-9. PubMed ID: 22799565
    [No Abstract]   [Full Text] [Related]  

  • 10. Prostate-specific antigen screening for prostate cancer in older men in the United States of America.
    Black A; Berg CD
    Gerontology; 2012; 58(4):331-6. PubMed ID: 22343605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PSA at 60 may predict risk of death from prostate cancer.
    Rees J
    Practitioner; 2010 Oct; 254(1733):5. PubMed ID: 21141246
    [No Abstract]   [Full Text] [Related]  

  • 12. Correlation between stage shift and differences in mortality in the European Randomised study of Screening for Prostate Cancer (ERSPC).
    Bokhorst LP; Zappa M; Carlsson SV; Kwiatkowski M; Denis L; Paez A; Hugosson J; Moss S; Auvinen A; Roobol MJ
    BJU Int; 2016 Nov; 118(5):677-680. PubMed ID: 27104278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Doing it right: how, not whether, to perform prostate-specific antigen screening.
    Martin NE
    Eur Urol; 2015 Sep; 68(3):361-2. PubMed ID: 25794459
    [No Abstract]   [Full Text] [Related]  

  • 14. Editorial comment.
    Berglund RK
    Urology; 2011 Jun; 77(6):1329; author reply 1329. PubMed ID: 21624593
    [No Abstract]   [Full Text] [Related]  

  • 15. Unorganized prostate-specific antigen-based screening for prostate cancer: more harm than benefit. When will we finally start to implement guidelines and risk assessment tools in clinical practice?
    Roobol MJ
    Eur Urol; 2015 Sep; 68(3):363-4. PubMed ID: 25769985
    [No Abstract]   [Full Text] [Related]  

  • 16. Prostate cancer screening can save lives but it is too early for a national programme, study finds.
    Sayburn A
    BMJ; 2014 Aug; 349():g5055. PubMed ID: 25102993
    [No Abstract]   [Full Text] [Related]  

  • 17. Editorial comment on: Insignificant prostate cancer and active surveillance: from definition to clinical implications.
    Aus G
    Eur Urol; 2009 Jun; 55(6):1331. PubMed ID: 19286303
    [No Abstract]   [Full Text] [Related]  

  • 18. Alternative prostate cancer screening strategies.
    Labrecque M; Aprikian A
    Ann Intern Med; 2013 May; 158(10):778. PubMed ID: 23689773
    [No Abstract]   [Full Text] [Related]  

  • 19. Re: Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-Specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study.
    Taneja SS
    J Urol; 2015 Aug; 194(2):393-4. PubMed ID: 26195364
    [No Abstract]   [Full Text] [Related]  

  • 20. Alternative prostate cancer screening strategies--in response.
    Gulati R; Etzioni R
    Ann Intern Med; 2013 May; 158(10):778-9. PubMed ID: 23689774
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.